18.08.2020 16:11
China’s first patent for a COVID-19 vaccine has been granted by the National Intellectual Property Administration, Xinhua News Agency reports.
The patent was jointly applied for by a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company.
According to the patent abstract, the vaccine shows good immunogenicity in both mouse and guinea pig models and can induce strong cellular and humoral immune response in a short period of time. It can be produced quickly on a large scale to cope with a COVID-19 outbreak.
The vaccine has now finished phase-1 and phase-2 clinical trials, which have verified its safety and immunogenicity.
